Sarepta Therapeutics 2026 JPMorgan Conference.pdf

《Sarepta Therapeutics 2026 JPMorgan Conference.pdf》由会员分享，可在线阅读，更多相关《Sarepta Therapeutics 2026 JPMorgan Conference.pdf（24页珍藏版）》请在三个皮匠报告上搜索。

1、SAREPTA THERAPEUTICS,INC.2026.ALL RIGHTS RESERVED.1 1Sarepta Therapeutics,Inc.(NASDAQ:SRPT)44th Annual J.P.Morgan Healthcare ConferenceSan Francisco,CaliforniaJANUARY 12,2026DOUG INGRAMChief Executive OfficerMAX,age 10Dosed with ELEVIDYS at age 5SAREPTA THERAPEUTICS,INC.2026.ALL RIGHTS RESERVED.2For

2、ward-looking statements In order to provide Sareptas investors with an understanding of its current results and future prospects,forward-looking statements will be made during this presentation.Any statements that are not statements of historical fact may be deemed to be forward-looking statements.W

3、ords such as“believe,”“anticipate,”“plan,”“expect,”“will,”“may,”“intend,”“prepare,”“look,”“potential,”“possible”and similar expressions are intended to identify forward-looking statements.These forward-looking statements include,without limitation,statements relating to our preliminary earnings,fina

4、ncial projections and future operations;our pipeline,priorities and strategies;ELEVIDYS and Cohort 8 of ENDEAVOR;the potential benefits and differentiation of our siRNA programs and TRiM platform;our ongoing and planned clinical trials;and expected plans and milestones,including meeting with FDA to

5、discuss a path to traditional approval of casimersen and golodirsen,and our expected near-term milestones in 2026 for various programs.Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties.Known risk factor

6、s include the following:our products or product candidates may be perceived as insufficiently effective,unsafe or may result in unforeseen adverse events;our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing app